Mechlorethamine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Topical Gel
Available Strengths: 0.016%
Reference Brands: Valchlor (USA), Ledaga (EU/LATAM/UK)
Category:
Oncology Cancer Care
Mechlorethamine Hydrochloride is available in Topical Gel
and strengths such as 0.016%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Mechlorethamine Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Mechlorethamine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Mechlorethamine is a nitrogen mustard and antineoplastic agent with a long history of clinical use spanning over six decades. Historically, it was administered systemically, often in combination with other chemotherapy agents, for the treatment of Hodgkin disease, chronic leukemias, lung cancer, and polycythemia vera. Its mechanism of action involves alkylating DNA, which disrupts the replication and growth of rapidly dividing cancer cells. This made mechlorethamine a cornerstone in early chemotherapy regimens, contributing to improved outcomes in hematologic and certain solid tumors.
Today, the primary use of mechlorethamine has shifted to dermatological applications, where it is formulated as a topical gel for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides. The topical gel allows localized therapy, targeting affected skin areas while minimizing systemic exposure. When previously given parenterally in combination therapy, mechlorethamine was associated with low rates of serum enzyme elevations, but it has not been linked to acute, clinically apparent liver injury. Its long-standing clinical use, combined with its proven efficacy in both systemic and topical applications, continues to make mechlorethamine an important therapeutic option in oncology and dermatology settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing